Wilson Therapeutics Progressing Its Copper Modulating Agent To Phase III
Bolstered by positive top-line Phase II trial data, Sweden-based Wilson Therapeutics will independently progress its copper modulating agent and lead asset into Phase III trials next year for the rare genetic condition known as Wilson's Disease.
You may also be interested in...
HealthCap’s Steen On Growing Successful Precision Medicine Businesses
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.
Corporate VCs Wade In With Funds To Pursue Gene Therapy For Wilson Disease
Rare copper-overload disorder Wilson disease is seeing a surge of interest: one new copper chelator recently garnered a CHMP recommendation, a novel copper modulator has had promising Phase II data, and French biotech Vivet has secured significant funds to pursue a gene therapy approach to the disease.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.